EIP
NKGN

Easterly Investment Partners’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Easterly Investment Partners’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$485K – 229
2021
Q3 		$485K Buy
+50,000
New +$488K 0.03% 168

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Easterly Investment Partners's NKGN Position: Q4 2021 in Review

Easterly Investment Partners sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2021, closing a stake of 50,000 shares — an estimated $485K sold.

Easterly Investment Partners first reported a position in NKGN in Q3 2021 and held it in 1 quarter. The position peaked at $485K in Q3 2021. 41 funds tracked by Wall St. Rank hold NKGN as of Q4 2021.

  • Easterly Investment Partners reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Easterly Investment Partners sold 50,000 NKGen Biotech, Inc. Common Stock shares in Q4 2021, an estimated $485K.
  • Easterly Investment Partners first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Easterly Investment Partners's NKGen Biotech, Inc. Common Stock position peaked at $485K in Q3 2021.
  • 41 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2021.

Based on Easterly Investment Partners's 13F filing for Q4 2021, filed 8 Feb 2022.